4//SEC Filing
Fridriksdottir Hafrun 4
Accession 0001209191-22-017046
CIK 0000818686other
Filed
Mar 7, 7:00 PM ET
Accepted
Mar 8, 4:07 PM ET
Size
24.2 KB
Accession
0001209191-22-017046
Insider Transaction Report
Form 4
Fridriksdottir Hafrun
Executive VP, Global R&D
Transactions
- Exercise/Conversion
Ordinary Shares
2022-03-04+51,488→ 116,996.514 total - Sale
Ordinary Shares
2022-03-04$7.48/sh−6,618$49,519→ 111,263.514 total - Award
Restricted Share Units
2022-03-04+140,750→ 140,750 total→ Ordinary Shares (140,750 underlying) - Exercise/Conversion
Restricted Share Units
2022-03-04−51,488→ 0 total→ Ordinary Shares (51,488 underlying) - Exercise/Conversion
Restricted Share Units
2022-03-04−18,905→ 18,906 total→ Ordinary Shares (18,905 underlying) - Sale
Ordinary Shares
2022-03-04$7.48/sh−18,020$134,835→ 98,976.514 total - Exercise/Conversion
Ordinary Shares
2022-03-04+18,905→ 117,881.514 total - Exercise/Conversion
Ordinary Shares
2022-03-05+23,764→ 135,027.514 total - Sale
Ordinary Shares
2022-03-07$7.37/sh−8,941$65,866→ 126,086.514 total - Exercise/Conversion
Restricted Share Units
2022-03-05−23,764→ 71,293 total→ Ordinary Shares (23,764 underlying)
Footnotes (10)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F10]Restricted share units were granted on March 5, 2021, with 23,764 having vested on March 5, 2022, 23,764 vesting on each of March 5, 2023 and March 5, 2024, and 23,765 vesting on March 5, 2025.
- [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- [F3]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F4]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.40 to $7.60, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.30 to $7.49, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F7]Restricted share units were received on February 8, 2022 upon satisfaction of performance criteria and vested on March 4, 2022.
- [F8]Restricted share units were granted on March 4, 2019, with 18,905 having vested on each of March 4, 2021 and March 4, 2022, and 18,906 vesting on March 4, 2023.
- [F9]Restricted share units were granted on March 4, 2022, with 35,187 vesting on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 35,189 vesting on March 4, 2026.
Documents
Issuer
TEVA PHARMACEUTICAL INDUSTRIES LTD
CIK 0000818686
Entity typeother
Related Parties
1- filerCIK 0001561458
Filing Metadata
- Form type
- 4
- Filed
- Mar 7, 7:00 PM ET
- Accepted
- Mar 8, 4:07 PM ET
- Size
- 24.2 KB